TIDMLEL
Jentadueto® (linagliptin/metformin hydrochloride) tablets recommended for
approval in the treatment of adults with type 2 diabetes in Europe
Milestone reflects the commitment of Boehringer Ingelheim and Eli Lilly and
Company in bringing new diabetes medicines to patients around the world who
need them
Ridgefield, CT and Indianapolis, IN, May 29, 2012 - Boehringer Ingelheim and
Eli Lilly and Company (NYSE: LLY) today announced they have received a positive
opinion from the European Medicines Agency's (EMA) medicinal committee
recommending approval of Jentadueto® (linagliptin/metformin hydrochloride)
tablets, a medicine combining the DPP-4 inhibitor, linagliptin (the active
ingredient in Tradjenta® tablets, marketed under the trade name Trajenta® in
Europe) and metformin in a single tablet taken twice daily.1
The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended the
approval of JENTADUETO for use alongside diet and exercise to improve glycemic
control in adults with type 2 diabetes who are inadequately controlled on their
maximally tolerated dose of metformin alone or those already being treated with
the combination of linagliptin and metformin. If approved by the European
Commission, JENTADUETO will provide a new, single-tablet treatment option,
taken twice daily, for adults with type 2 diabetes who need to improve control
of their blood glucose.2
"The CHMP positive opinion for JENTADUETO marks another important regulatory
milestone for the Boehringer Ingelheim and Eli Lilly and Company worldwide
diabetes alliance, extending our commitment to bringing new medicines to those
patients who need them," said Prof. Klaus Dugi, Corporate Senior Vice President
Medicine, Boehringer Ingelheim. "Around the world, many people with type 2
diabetes require more than one treatment to adequately manage their blood
sugar. By combining two important diabetes medicines in a single tablet, we
believe that JENTADUETO will provide people with type 2 diabetes another way of
improving control of their blood sugar."
JENTADUETO was approved by the U.S. Food and Drug Administration (FDA) in
January 2012 as a prescription medicine used along with diet and exercise to
improve glycemic control in adults with type 2 diabetes when treatment with
both linagliptin and metformin is appropriate.1 In clinical studies, initial
combination therapy with JENTADUETO was superior to metformin monotherapy and
to placebo in improving hemoglobin A1c (HbA1c or A1C) and fasting plasma
glucose (FPG), with a similar safety and tolerability profile. No meaningful
change in body weight was noted in any treatment group.1
At the maximum dose of 2.5 mg (linagliptin)/1000mg (metformin HCl) BID,
JENTADUETO demonstrated placebo-corrected reductions in A1C levels of up to 1.7
percent (+0.1 percent for placebo and -1.6 percent for JENTADUETO).1 A1C is
measured in people with diabetes to provide an index of blood glucose control
for the previous two to three months. JENTADUETO did not cause any meaningful
change in body weight.1 JENTADUETO can be used alone or in combination with a
sulfonylurea, a commonly prescribed medication for type 2 diabetes. JENTADUETO
is not for the treatment of type 1 diabetes or diabetic ketoacidosis (increased
ketones in the blood or urine). It has not been studied in combination with
insulin.1 The JENTADUETO U.S. label contains a boxed warning for the risk of
lactic acidosis, a serious metabolic complication that can occur due to
metformin accumulation during treatment with JENTADUETO.1
Adverse reactions reported in greater than or equal to five percent of patients
treated with JENTADUETO and more commonly than in patients treated with placebo
included nasopharyngitis (the common cold) and diarrhea. Hypoglycemia was more
commonly reported in patients treated with the combination of JENTADUETO and
sulfonylurea compared with those treated with the combination of placebo,
sulfonylurea and metformin. Pancreatitis was reported more often in patients
randomized to linagliptin (1 per 538 person-years versus zero in 433
person-years for comparator).1
Linagliptin (5 mg, once daily) is marketed as Trajenta® across Europe and
Canada, as Tradjenta® in the US, and Trazenta® in Japan, as well as in
additional markets.
About Diabetes
Approximately 25.8 million Americans3 and an estimated 366 million people
worldwide4 have type 1 and type 2 diabetes. Type 2 diabetes is the most common
type, accounting for an estimated 90 to 95 percent of all diabetes cases.3
Diabetes is a chronic disease that occurs when the body either does not
properly produce, or use, the hormone insulin.5
What is JENTADUETO?
JENTADUETO is a prescription medicine that contains 2 diabetes medicines,
linagliptin and metformin. JENTADUETO can be used along with diet and exercise
to help control blood sugar in adults with type 2 diabetes when treatment with
both linagliptin and metformin is appropriate.
JENTADUETO is not for people with type 1 diabetes or for people with diabetic
ketoacidosis (increased ketones in the blood or urine).
It is not known if JENTADUETO is safe and effective when used with insulin.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about JENTADUETO?
WARNING: RISK OF LACTIC ACIDOSIS
Serious side effects can happen in people taking JENTADUETO.
Metformin, one of the medicines in JENTADUETO, can cause a rare
but serious condition called lactic acidosis (a build-up of
lactic acid in the blood) that can cause death. Lactic acidosis
is a medical emergency and must be treated in a hospital.
Stop taking JENTADUETO and call your doctor right away if you
feel very weak or tired, have unusual muscle pain, have trouble
breathing, are very sleepy, have sudden nausea and vomiting or
diarrhea, feel cold, especially in your arms or legs, feel dizzy
or lightheaded, or have a slow or irregular heartbeat, as these
could be symptoms of lactic acidosis.
You have a higher chance of getting lactic acidosis with
JENTADUETO if you have kidney problems, liver problems,
congestive heart failure that requires medicines, drink alcohol
very often, or drink a lot of alcohol in short-term "binge"
drinking, get dehydrated (lose a large amount of body fluids),
have certain x-ray tests with dyes or contrast agents that are
injected into your body, have surgery, have a heart attack,
severe infection, or stroke, and are 80 years of age or older
and have not had your kidneys tested.
Who should not take JENTADUETO?
Do not take JENTADUETO if you:
* have kidney problems
* have a condition called metabolic acidosis or diabetic ketoacidosis
(increased ketones in the blood or urine)
* are allergic to linagliptin, metformin or any of the ingredients in
JENTADUETO. Symptoms of any allergic reaction are rash, raised red patches
on your skin (hives), and swelling of your face, lips, and throat that may
cause difficulty breathing or swallowing. If you have any symptoms of a
serious allergic reaction, stop taking JENTADUETO and call your doctor
right away.
What should I tell my doctor before using JENTADUETO?
Before you take JENTADUETO, tell your doctor if you:
* have kidney problems
* are going to get an injection of dye or contrast agents for an x-ray
procedure. JENTADUETO will need to be stopped for a short time. Talk to
your doctor about when you should stop JENTADUETO and when you should start
JENTADUETO again.
* have liver problems
* have heart problems, including congestive heart failure
* drink alcohol very often, or drink a lot of alcohol in short term "binge"
drinking
* have any other medical conditions
* are pregnant or planning to become pregnant. It is not known if JENTADUETO
will harm your unborn baby. If you are pregnant, talk with your doctor
about the best way to control your blood sugar while you are pregnant.
* are breast-feeding or plan to breast-feed. It is not known if JENTADUETO
passes into your breast milk. Talk with your doctor about the best way to
feed your baby if you take JENTADUETO.
Tell your doctor about all the medicines you take, including prescription and
non-prescription medicines, vitamins, and herbal supplements. JENTADUETO may
affect the way other medicines work, and other medicines may affect how
JENTADUETO works.
Especially tell your doctor if you take:
* other medicines that can lower your blood sugar. JENTADUETO may cause
serious side effects, including low blood sugar (hypoglycemia), which may
become worse in people who already take another medication to treat
diabetes, such as a sulfonylurea or insulin. Tell your healthcare provider
if you take other diabetes medicines. Your doctor may prescribe lower doses
of the sulfonylurea medicine.
If you have symptoms of low blood sugar, you should check your blood sugar and
treat it if it is low, then call your healthcare provider. Symptoms of low
blood sugar include shaking, rapid heartbeat, hunger, headache, sweating,
change in vision, and change in mood.
* rifampin (Rifadine®, Rimactane®, Rifater®, Rifamate®), an antibiotic that
is used to treat tuberculosis.
Ask your doctor or pharmacist for a list of these medicines if you are not sure
if your medicine is one that is listed above.
Know the medicines you take. Keep a list of them and show it to your doctor and
pharmacist when you get a new medicine.
What are the possible side effects of JENTADUETO tablets?
The most common side effects of JENTADUETO include:
* stuffy or runny nose and sore throat
* diarrhea
You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Important Safety Information including Boxed Warning about the Risk
of Lactic Acidosis, and full Prescribing Information, including Patient
Information for additional safety information.
To learn more about JENTADUETO visit http://www.JENTADUETO.com. For full
prescribing information visit http://bidocs.boehringer-ingelheim.com/
BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information
/PIs/Jentadueto/Jentadueto.pdf or call Boehringer Ingelheim Pharmaceuticals,
Inc. at 1-800-542-6257, or (TTY) 1-800-459-9906.
Please report any unexpected effects or product problems to the Boehringer
Ingelheim Drug Information Unit by calling 1-800-542-6257.
What are TRADJENTA tablets?
TRADJENTA is a prescription medicine that is used along with diet and exercise
to lower blood sugar in adults with type 2 diabetes.
Tradjenta is not for people with type 1 diabetes or for people with diabetic
ketoacidosis (increased ketones in the blood or urine).
It is not known if TRADJENTA is safe and effective when used with insulin.
Important Safety Information
Who should not take TRADJENTA?
Do not take TRADJENTA if you are allergic to linagliptin or any of the
ingredients in TRADJENTA.
Symptoms of a serious allergic reaction to TRADJENTA are rash, raised red
patches on your skin (hives), swelling of your face, lips, and throat that may
cause difficulty breathing or swallowing. If you have any symptoms of a serious
allergic reaction, stop taking TRADJENTA and call your doctor right away.
What should I tell my doctor before taking TRADJENTA?
Tell your doctor if you take other medicines that can lower your blood sugar,
such as a sulfonylurea or insulin.
TRADJENTA may cause serious side effects, including low blood sugar
(hypoglycemia). If you take TRADJENTA with another medicine that can cause low
blood sugar, such as sulfonylurea or insulin, your risk of getting low blood
sugar is higher. The dose of your sulfonylurea medicine or insulin may need to
be lowered while you take TRADJENTA.
Signs and symptoms of low blood sugar may include headache, drowsiness,
weakness, dizziness, confusion, irritability, hunger, fast heartbeat, sweating,
or feeling jittery.
Also tell your doctor if you take rifampin (Rifadin®, Rimactane®, Rifater®,
Rifamate®), an antibiotic that is used to treat tuberculosis.
TRADJENTA may affect the way other medicines work, and other medicines may
affect how TRADJENTA works.
Tell your doctor if you are pregnant or planning to become pregnant or are
breast-feeding or plan to breast-feed.
Tell your doctor about all the medicines you take, including prescription and
non-prescription medicines, vitamins, and herbal supplements.
What are the possible side effects of TRADJENTA?
The most common side effects of TRADJENTA include stuffy or runny nose and sore
throat.
You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
For more safety information, please see Patient Information and full
Prescribing Information.
To learn more about TRADJENTA visit: www.TRADJENTA.com. For full prescribing
information visit: http://bidocs.boehringer-ingelheim.com/BIWebAccess/
ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/
Tradjenta/Tradjenta.pdf or call Boehringer Ingelheim Pharmaceuticals, Inc. at
1-800-542-6257.
Please report any unexpected effects or product problems to the Boehringer
Ingelheim Drug Information Unit by calling 1-800-542-6257.
Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Companyannounced an
alliance in the field of diabetes that centers on four pipeline compounds
representing several of the largest treatment classes. This alliance leverages
the companies' strengths as two of the world's leading pharmaceutical
companies, combining Boehringer Ingelheim's solid track record of
research-driven innovation and Lilly's innovative research, experience, and
pioneering history in diabetes. By joining forces, the companies demonstrate
commitment in the care of patients with diabetes and stand together to focus on
patient needs. Find out more about the alliance at www.boehringer-ingelheim.com
or www.lilly.com.
About Boehringer Ingelheim Pharmaceuticals, Inc.
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical
companies. Headquartered in Ingelheim, Germany, it operates globally with 145
affiliates and more than 44,000 employees. Since it was founded in 1885, the
family-owned company has been committed to researching, developing,
manufacturing and marketing novel medications of high therapeutic value for
human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act
socially responsible. Involvement in social projects, caring for employees and
their families, and providing equal opportunities for all employees form the
foundation of the global operations. Mutual cooperation and respect, as well as
environmental protection and sustainability are intrinsic factors in all of
Boehringer Ingelheim's endeavors.
In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2
billion euro). R&D expenditure in the business area Prescription Medicines
corresponds to 23.5% of its net sales.
For more information, please visit http://us.boehringer-ingelheim.com and
follow us on Twitter at http://twitter.com/boehringerus.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, IN, Lilly provides answers -
through medicines and information - for some of the world's most urgent medical
needs. Additional information about Lilly is available at www.lilly.com.
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced
the world's first commercial insulin. Today we work to meet the diverse needs
of people with diabetes through research and collaboration, a broad and growing
product portfolio and a continued commitment to providing real solutions--from
medicines to support programs and more--to make lives better.
This press release contains forward-looking statements about JENTADUETO for the
treatment of type 2 diabetes. It reflects Lilly's current beliefs; however, as
with any such undertaking, there are substantial risks and uncertainties in the
process of drug development and commercialization. There is no guarantee that
future study results and patient experience will be consistent with study
findings to date or that JENTADUETO will be approved for marketing or will be
commercially successful. For further discussion of these and other risks and
uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the
U.S. Securities and Exchange Commission. Lilly undertakes no duty to update
forward-looking statements.
P-LLY
JD189300
###
CONTACT:
Lara Crissey
Director of Communications and Public Relations
Boehringer Ingelheim Pharmaceuticals, Inc.
Email: usnews@boehringer-ingelheim.com
Phone: (203) 798-4740
Tammy Hull
Communications Manager
Lilly Diabetes
Email: hullta@lilly.com
Phone: (317) 651-9116
1. Jentadueto® (linagliptin/metformin HCI) tablets. Highlights of Prescribing
Information. Initial US Approval: 2012
2. Data on File
3. Centers for Disease Control and Prevention. National diabetes fact sheet:
national estimates and general information on diabetes and prediabetes in
the United States, 2011. Atlanta, GA: U.S. Department of health and Human
Services, Center for Disease Control and Prevention, 2011.
4. International Diabetes Federation. Diabetes Atlas, 5th Edition: Fact Sheet.
2011.
5. International Diabetes Federation. Diabetes Atlas, 5th Edition: What is
Diabetes? http://www.idf.org/diabetesatlas/5e/what-is-diabetes. Accessed
on: February 22, 2012.
Press Release
For U.S. Media
END
Lilly(Eli) (LSE:LEL)
Historical Stock Chart
From Jan 2025 to Feb 2025
Lilly(Eli) (LSE:LEL)
Historical Stock Chart
From Feb 2024 to Feb 2025
